IGFBP6 and Cognitive impairment: Using predictive analysis of microarrays, a previous study demonstrated that a panel of 18 plasma proteins (CCL18, CCL15, CCL7, CXCL8, ICAM-1, TRAIL-R4, G-CSF, GDNF, EGF, CCL5, M-CSF, IL-3, IL-1α, TNF-α, PDGF-BB, IL-11, ANG-2, and IGFBP-6) achieved a diagnostic accuracy of 90% in distinguishing AD and mild cognitive impairment (MCI) (Ray et al., 2007), which was reported to be unable to distinguish patients with AD from the populations through enough diagnostic precision (Bjorkqvist et al., 2012).